Form 4: NKGen Biotech Sees Significant Insider Investment with $2.5 Million Share Purchase and Warrant Issuance

CFIC-2015 NV Family Investments, LLC, a 10% owner and entity controlled by directors Andrew and Peggy Cherng, has acquired over 19.6 million shares and received warrants for an additional 39.3 million shares of NKGen Biotech, Inc. common stock.

Summary

• CFIC-2015 NV Family Investments, LLC, a reporting person identified as a Director and 10% Owner of NKGen Biotech, Inc. (NKGN), completed a significant transaction.
• On May 27, 2025, CFIC-2015 purchased 19,669,552 shares of NKGen Biotech's common stock at a price of $0.1271 per share, totaling an aggregate purchase price of $2,500,000.00.
• This purchase was made pursuant to a Stock Purchase Agreement dated May 14, 2025, between CFIC-2015 and NKGen Biotech.
• Following this transaction, CFIC-2015 beneficially owns 21,752,885 shares of common stock.
• Additionally, on May 27, 2025, NKGen Biotech issued a common stock purchase warrant to CFIC-2015 for the purchase of up to 39,339,103 shares of common stock.
• The warrant is exercisable at the same price of $0.1271 per share and expires on May 27, 2030.
• Andrew Cherng and Peggy Cherng, also listed as Directors and 10% Owners, together own 100% of the voting interests of CFIC-2015 NV Family Investments, LLC.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to a substantial insider investment by a 10% owner and directors, indicating strong confidence in the company's future and providing a significant capital injection.

Positives

• A significant insider purchase of 19,669,552 shares at $0.1271 per share demonstrates strong confidence from key stakeholders, including directors and a 10% owner.
• The investment of $2.5 million provides a capital infusion to NKGen Biotech, which can support its operations and strategic initiatives.
• The issuance of a warrant for an additional 39,339,103 shares at the same exercise price indicates a long-term commitment and potential for further capital injection if the warrant is exercised.
• The transaction involves entities directly controlled by Andrew Cherng and Peggy Cherng, who are significant figures within the company's governance structure.

Future Outlook

The issuance of a common stock purchase warrant exercisable until May 27, 2030, suggests a potential future capital infusion for NKGen Biotech if the warrant is exercised, indicating a long-term investment perspective from the reporting entity.

Management Comments

• Andrew Cherng and Peggy Cherng, through their ownership of CFIC-2015 NV Family Investments, LLC, have demonstrated significant financial commitment to NKGen Biotech, signaling strong confidence in the company's future by investing $2.5 million and securing warrants for additional shares.

Industry Context

This Form 4 filing details a company-specific insider transaction and capital raise, rather than broader industry trends. However, significant insider investment in a biotech company can be viewed positively, especially in a sector that often requires substantial capital for research, development, and commercialization.

Comparison to Industry Standards

• While direct comparisons to specific companies or projects are not provided in a Form 4, insider purchases of this magnitude (a $2.5 million investment coupled with warrants for double the shares) are generally seen as a strong vote of confidence, often exceeding typical open-market purchases by individual insiders in terms of scale.
• The purchase price of $0.1271 per share, while low, represents the agreed-upon valuation for this specific capital raise, which may be below market price if the stock has traded higher, or reflect a strategic investment at a perceived low point.

Related Party Transactions

• The transaction involves CFIC-2015 NV Family Investments, LLC, which is a 10% owner and whose voting interests are 100% owned by Andrew Cherng and Peggy Cherng, both listed as Directors of NKGen Biotech, Inc. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The significant insider purchase and warrant issuance can be viewed as a strong vote of confidence, potentially boosting investor sentiment and signaling alignment of interests between management/major owners and shareholders.
• Company: The $2.5 million capital infusion strengthens the company's financial position, providing resources for ongoing operations, research, and development.

Next Steps

• Potential exercise of the 39,339,103 common stock purchase warrants by CFIC-2015 NV Family Investments, LLC at an exercise price of $0.1271 per share, which could occur anytime until May 27, 2030.

Key Dates

Recommendation

Keywords

NKGen Biotech, NKGN, Insider Trading, Stock Purchase, Warrant, Beneficial Ownership, SEC Form 4, Capital Raise, Biotech Investment